Aurinia Pharmaceuticals (AUPH)

• Market cap: $2.04B
• 1 day: 0.91%
• 5 days: 1.98%
• 1 month: -0.39%
• 3 months: 33.13%
• 6 months: 84.39%
• Year to date: 0.78%
• 1 year: 91.7%
• 5 years: 9.56%
• 10 years: 590.63%
• Sector: Healthcare
• Industry: Biotechnology

About: Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Employees: 300